Bone, the major structural scaffold of the human body, has recently been demonstrated to interact with several other organ systems through the actions of bone-derived cells and bone-derived cell secretory proteins. Interestingly, the brain is one organ that appears to fall into this interconnected network. Furthermore, the fact that osteoporosis and Alzheimer’s disease are two common age-related disorders raises the possibility that these two organ systems are interconnected in terms of disease pathogenesis. This review focuses on the latest evidence demonstrating the impact of bone-derived cells and bone-derived proteins on the central nervous system, and on how this may be relevant in the progression of Alzheimer’s disease and for the identification of novel therapeutic approaches to treat this neurodegenerative disorder.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
3.
NayakS, GreenspanSL (2018) How can we improve osteoporosis care? A systematic review and meta-analysis of the efficacy of quality improvement strategies for osteoporosis. J Bone Miner Res33, 1585–1594.
4.
HainesJL (2018) Alzheimer disease: Perspectives from epidemiology and genetics. J Law Med Ethics46, 694–698.
5.
RachnerTD, KhoslaS, HofbauerLC (2011) Osteoporosis: Now and the future. Lancet377, 1276–1287.
6.
CenterJR, NguyenTV, SchneiderD, SambrookPN, EismanJA (1999) Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet353, 878–882.
7.
DowneyCL, YoungA, BurtonEF, GrahamSM, MacfarlaneRJ, TsapakisEM, TsiridisE (2017) Dementia and osteoporosis in a geriatric population: Is there a common link?World J Orthop8, 412–423.
8.
ZhaoY, ShenL, JiHF (2012) Alzheimer’s disease and risk of hip fracture: A meta-analysis study. ScientificWorldJournal2012, 872173.
9.
KangHG, ParkHY, RyuHU, SukSH (2018) Bone mineral loss and cognitive impairment: The PRESENT project. Medicine (Baltimore)97, e12755.
10.
ZhouR, DengJ, ZhangM, ZhouHD, WangYJ (2011) Association between bone mineral density and the risk of Alzheimer’s disease. J Alzheimers Dis24, 101–108.
11.
ChenYH, LoRY (2017) Alzheimer’s disease and osteoporosis. Ci Ji Yi Xue Za Zhi29, 138–142.
12.
SatoY, KanokoT, SatohK, IwamotoJ (2004) Risk factors for hip fracture among elderly patients with Alzheimer’s disease. J Neurol Sci223, 107–112.
YuedeCM, TimsonBF, HettingerJC, YuedeKM, EdwardsHM, LawsonJE, ZimmermanSD, CirritoJR (2018) Interactions between stress and physical activity on Alzheimer’s disease pathology. Neurobiol Stress8, 158–171.
15.
OteroM, EsainI, Gonzalez-SuarezAM, GilSM (2017) The effectiveness of a basic exercise intervention to improve strength and balance in women with osteoporosis. Clin Interv Aging12, 505–513.
16.
SolomonA, MangialascheF, RichardE, AndrieuS, BennettDA, BretelerM, FratiglioniL, HooshmandB, KhachaturianAS, SchneiderLS, SkoogI, KivipeltoM (2014) Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med275, 229–250.
17.
RaberJ, HuangY, AshfordJW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging25, 641–650.
18.
NoguchiT, EbinaK, HiraoM, OtsuruS, GuessAJ, KawaseR, OhamaT, YamashitaS, EtaniY, OkamuraG, YoshikawaH (2018) Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-kappaB pathway. Biochem Biophys Res Commun503, 644–650.
TasakiS, GaiteriC, MostafaviS, De JagerPL, BennettDA (2018) The molecular and neuropathological consequences of genetic risk for Alzheimer’s dementia. Front Neurosci12, 699.
23.
BurkeSL, CadetT, AlcideA, O’DriscollJ, MaramaldiP (2018) Psychosocial risk factors and Alzheimer’s disease: The associative effect of depression, sleep disturbance, and anxiety. Aging Ment Health22, 1577–1584.
24.
CavedoE, ChiesaPA, HouotM, FerrettiMT, GrotheMJ, TeipelSJ, ListaS, HabertMO, PotierMC, DuboisB, HampelH (2018) Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer’s disease in cognitively normal older adults with subjective memory complaints. Alzheimers Dement14, 1204–1215.
25.
RanaM, SharmaAK (2019) Cu and Zn interactions with Abeta peptides: Consequence of coordination on aggregation and formation of neurotoxic soluble Abeta oligomers. Metallomics11, 64–84.
26.
SundstromA, NilssonLG, CrutsM, AdolfssonR, Van BroeckhovenC, NybergL (2007) Increased risk of dementia following mild head injury for carriers but not for non-carriers of the APOE epsilon4 allele. Int Psychogeriatr19, 159–165.
27.
CerajewskaTL, DaviesM, WestNX (2015) Periodontitis: A potential risk factor for Alzheimer’s disease. Br Dent J218, 29–34.
DuaraR, BarkerW, LoewensteinD, BainL (2009) The basis for disease-modifying treatments for Alzheimer’s disease: The Sixth Annual Mild Cognitive Impairment Symposium. Alzheimers Dement5, 66–74.
30.
SelkoeDJ (2001) Presenilin, Notch, and the genesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A98, 11039–11041.
31.
GoldeTE, MillerVM (2009) Proteinopathy-induced neuronal senescence: A hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases. Alzheimers Res Ther1, 5.
32.
SelkoeDJ, HardyJ (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med8, 595–608.
33.
FerreiraST, ClarkeJR, BomfimTR, De FeliceFG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimers Dement10, S76–S83.
34.
HanY, YouX, XingW, ZhangZ, ZouW (2018) Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res6, 16.
35.
FengX, McDonaldJM (2011) Disorders of bone remodeling. Annu Rev Pathol6, 121–145.
36.
de BaaijJH, HoenderopJG, BindelsRJ (2015) Magnesium in man: Implications for health and disease. Physiol Rev95, 1–46.
37.
SadowskiKJ,
RobertsF LA
(2017) Skeletal energy homeostasis: A paradigm of endocrine discovery. J Endocrinol234, R67–R79.
38.
RaggattLJ, PartridgeNC (2010) Cellular and molecular mechanisms of bone remodeling. J Biol Chem285, 25103–25108.
39.
BeckerC (2006) Pathophysiology and clinical manifestations of osteoporosis. Clin Cornerstone8, 19–27.
40.
SimsNA, MartinTJ (2014) Coupling the activities of bone formation and resorption: A multitude of signals within the basic multicellular unit. Bonekey Rep3, 481.
41.
HoltropME, KingGJ (1977) The ultrastructure of the osteoclast and its functional implications. Clin Orthop Relat Res177–196.
42.
RossFP (2011) Chapter 18 - Osteoclasts. In Vitamin D (Third Edition),
FeldmanD,
PikeJW,
AdamsJS, eds. Academic Press, San Diego, pp. 335–347.
43.
Florencio-SilvaR, SassoGR, Sasso-CerriE, SimoesMJ, CerriPS (2015) Biology of bone tissue: Structure, function, and factors that influence bone cells. Biomed Res Int2015, 421746.
44.
CrockettJC, RogersMJ, CoxonFP, HockingLJ, HelfrichMH (2011) Bone remodelling at a glance. J Cell Sci124, 991–998.
45.
HaradaS, RodanGA (2003) Control of osteoblast function and regulation of bone mass. Nature423, 349–355.
46.
CoughlanT, DockeryF (2014) Osteoporosis and fracture risk in older people. Clin Med (Lond)14, 187–191.
47.
QuarlesLD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol8, 276–286.
48.
LeeNK, SowaH, HinoiE, FerronM, AhnJD, ConfavreuxC, DacquinR, MeePJ, McKeeMD, JungDY, ZhangZ, KimJK, Mauvais-JarvisF, DucyP, KarsentyG (2007) Endocrine regulation of energy metabolism by the skeleton. Cell130, 456–469.
49.
FerronM, WeiJ, YoshizawaT, Del FattoreA, DePinhoRA, TetiA, DucyP, KarsentyG (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell142, 296–308.
50.
OuryF, SumaraG, SumaraO, FerronM, ChangH, SmithCE, HermoL, SuarezS, RothBL, DucyP, KarsentyG (2011) Endocrine regulation of male fertility by the skeleton. Cell144, 796–809.
HauschkaPV, LianJB, GallopPM (1975) Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A72, 3925–3929.
53.
PricePA, OtsukaAA, PoserJW, KristaponisJ, RamanN (1976) Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A73, 1447–1451.
ObriA, KhrimianL, KarsentyG, OuryF (2018) Osteocalcin in the brain: From embryonic develoment to age-related decline in cognition. Nat Rev Endocrinol14, 174–182.
60.
ArdawiMSM, QariMH, RouziAA, FaqeehWM, Al-SibianiSA, AkbarDH, AlShaikhAA (2011) Increased serum osteopontin is a risk factor for low bone mineral density and/or osteoporosis. Bone48, S196–S197.
61.
LundSA, GiachelliCM, ScatenaM (2009) The role of osteopontin in inflammatory processes. J Cell Commun Signal3, 311–322.
ReinholtFP, HultenbyK, OldbergA, HeinegardD (1990) Osteopontin–a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A87, 4473–4475.
64.
ChoEH, ChoKH, LeeHA, KimSW (2013) High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci28, 1496–1499.
65.
FodorD, BondorC, AlbuA, SimonSP, CraciunA, MunteanL (2013) The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. J Investig Med61, 15–21.
66.
BrownA (2012) Osteopontin: A key link between immunity, inflammation and the central nervous system. Transl Neurosci3, 288–293.
67.
ChanJL, ReevesTM, PhillipsLL (2014) Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury. Exp Neurol261, 757–771.
68.
GliemM, KrammesK, LiawL, van RooijenN, HartungHP, JanderS (2015) Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia63, 2198–2207.
69.
SunY, YinXS, GuoH, HanRK, HeRD, ChiLJ (2013) Elevated osteopontin levels in mild cognitive impairment and Alzheimer’s disease. Mediators Inflamm2013, 615745.
70.
JongbloedW, van DijkKD, MulderSD, van de BergWD, BlankensteinMA, van der FlierW, VeerhuisR (2015) Clusterin levels in plasma predict cognitive decline and progression to Alzheimer’s disease. J Alzheimers Dis46, 1103–1110.
71.
RentsendorjA, SheynJ, FuchsD-T, DaleyD, SalumbidesBC, SchubloomHE, HartNJ, LiS, HaydenEY, TeplowDB, BlackKL, KoronyoY, Koronyo-HamaouiM (2018) A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer’s models. Brain Behav Immun67, 163–180.
72.
LinYH, Yang-YenHF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem276, 46024–46030.
73.
CarecchioM, ComiC (2011) The role of osteopontin in neurodegenerative diseases. J Alzheimers Dis25, 179–185.
74.
ShahAD, ShobackD, LewieckiEM (2015) Sclerostin inhibition: A novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health7, 565–580.
75.
MorrellAE, BrownGN, RobinsonST, SattlerRL, BaikAD, ZhenG, CaoX, BonewaldLF, JinW, KamLC, GuoXE (2018) Mechanically induced Ca(2+) oscillations in osteocytes release extracellular vesicles and enhance bone formation. Bone Res6, 6.
76.
Roser-PageS, VikulinaT, WeissD, HabibMM, BeckGRJr., PacificiR, LaneTF, WeitzmannMN (2018) CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin. Ann N Y Acad Sci1415, 21–33.
BaronR, KneisselM (2013) WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med19, 179–192.
79.
MacDonaldBT, TamaiK, HeX (2009) Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell17, 9–26.
80.
LoganCY, NusseR (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol20, 781–810.
81.
InestrosaN, De FerrariGV, GarridoJL, AlvarezA, OlivaresGH, BarriaMI, BronfmanM, ChaconMA (2002) Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem Int41, 341–344.
82.
InestrosaNC, Varela-NallarL (2014) Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol6, 64–74.
83.
ScaliC, CaraciF, GianfriddoM, DiodatoE, RoncaratiR, PollioG, GaviraghiG, CopaniA, NicolettiF, TerstappenGC, CaricasoleA (2006) Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis24, 254–265.
84.
ToledoEM, InestrosaNC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry15, 272–285, 228.
85.
PurroSA, DickinsEM, SalinasPC (2012) The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J Neurosci32, 3492–3498.
86.
MarzoA, GalliS, LopesD, McLeodF, PodpolnyM, Segovia-RoldanM, CianiL, PurroS, CacucciF, GibbA, SalinasPC (2016) Reversal of synapse degeneration by restoring Wnt signaling in the adult hippocampus. Curr Biol26, 2551–2561.
87.
YinT, LiL (2006) The stem cell niches in bone. J Clin Invest116, 1195–1201.
88.
ThemistocleousGS, ChlorosGD, KyrantzoulisIM, GeorgokostasIA, ThemistocleousMS, PapagelopoulosPJ, SavvidouOD (2018) Effectiveness of a single intra-articular bone marrow aspirate concentrate (BMAC) injection in patients with grade 3 and 4 knee osteoarthritis. Heliyon4, e00871.
89.
LawsonLJ, PerryVH, GordonS (1992) Turnover of resident microglia in the normal adult mouse brain. Neuroscience48, 405–415.
90.
DeczkowskaA, Keren-ShaulH, WeinerA, ColonnaM, SchwartzM, AmitI (2018) Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell173, 1073–1081.
91.
SongWM, ColonnaM (2018) The identity and function of microglia in neurodegeneration. Nat Immunol19, 1048–1058.
92.
ItagakiS, McGeerPL, AkiyamaH, ZhuS, SelkoeD (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol24, 173–182.
93.
McGeerPL, ItagakiS, BoyesBE, McGeerEG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology38, 1285–1291.
94.
SappE, KegelKB, AroninN, HashikawaT, UchiyamaY, TohyamaK, BhidePG, VonsattelJP, DiFigliaM (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol60, 161–172.
95.
LampronA, GosselinD, RivestS (2011) Targeting the hematopoietic system for the treatment of Alzheimer’s disease. Brain Behav Immun25Suppl 1, S71–79.
96.
StreitWJ, SammonsNW, KuhnsAJ, SparksDL (2004) Dystrophic microglia in the aging human brain. Glia45, 208–212.
97.
NjieEG, BoelenE, StassenFR, SteinbuschHW, BorcheltDR, StreitWJ (2012) Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging33, 195.e191–112.
HanKH, ArlianBM, MacauleyMS, PaulsonJC, LernerRA (2018) Migration-based selections of antibodies that convert bone marrow into trafficking microglia-like cells that reduce brain amyloid beta. Proc Natl Acad Sci U S A115, E372–E381.
100.
El KhouryJ, LusterAD (2008) Mechanisms of microglia accumulation in Alzheimer’s disease: Therapeutic implications. Trends Pharmacol Sci29, 626–632.
101.
MalmTM, KoistinahoM, PärepaloM, VatanenT, OokaA, KarlssonS, KoistinahoJ (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis18, 134–142.
102.
SimardAR, SouletD, GowingG, JulienJP, RivestS (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron49, 489–502.
103.
WuC-C, WangIF, ChiangP-M, WangL-C, ShenC-KJ, TsaiK-J (2016) G-CSF-mobilized bone marrow mesenchymal stem cells replenish neural lineages in Alzheimer’s disease mice via CXCR4/SDF-1 hemotaxis. Mol Neurobiol54, 6198–6212.
104.
BorlonganCV, GloverLE, TajiriN, KanekoY, FreemanTB (2011)The great migration of bone marrow-derived stem cells toward the ischemic brain: Theraeutic implications for stroke and other neurological disorders. Prog Neurobiol95, 213–228.
105.
Sanchez-RamosJ, SongS, CaoC, ArendashG (2008) The potential of hematopoietic growth factors for treatment of Alzheimer’s disease: A mini-review. BMC Neurosci9Suppl 2, S3.
106.
WuJ, ZhangW, RanQ, XiangY, ZhongJF, LiSC, LiZ (2018) The differentiation balance of bone marrow mesenchymal stem cells is crucial to hematopoiesis. Stem Cells Int2018, 1540148.
107.
InfanteA, RodriguezCI (2018) Osteogenesis and aging: Lessons from mesenchymal stem cells. Stem Cell Res Ther9, 244.
108.
NaaldijkY, JagerC, FabianC, LeovskyC, BluherA, RudolphL, HinzeA, StolzingA (2017) Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathol Appl Neurobiol43, 299–314.
109.
GarciaKO, OrnellasFL, MartinPK, PattiCL, MelloLE, Frussa-FilhoR, HanSW, LongoBM (2014) Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer’s disease. Front Aging Neurosci6, 30.
110.
GrillJD, CummingsJL (2010) Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev Neurother10, 711–728.
111.
GodynJ, JonczykJ, PanekD, MalawskaB (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep68, 127–138.
112.
CartierN, LewisCA, ZhangR, RossiFM (2014) The role of microglia in human disease: Therapeutic tool or target?Acta Neuropathol128, 363–380.
KawanishiS, TakataK, ItezonoS, NagayamaH, KonoyaS, ChisakiY, TodaY, NakataS, YanoY, KitamuraY, AshiharaE (2018) Bone-marrow-derived microglia-like cells ameliorate brain amyloid pathology and cognitive impairment in a mouse model of Alzheimer’s disease. J Alzheimers Dis64, 563–585.
115.
ParkSE, LeeNK, NaDL, ChangJW (2018) Optimal mesenchymal stem cell delivery routes to enhance neurogenesis for the treatment of Alzheimer’s disease: Optimal MSCs delivery routes for the treatment of AD. Histol Histopathol33, 533–541.
116.
TsaiK-J, TsaiY-C, ShenC-KJ (2007) G-CSF rescues the memory impairment of animal models of Alzheimer’s disease. J Exp Med204, 1273–1280.
117.
ShinJW, LeeJK, LeeJE, MinWK, SchuchmanEH, JinHK, BaeJS (2011) Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1alpha in an Alzheimer’s disease mouse model. Stem Cells29, 1075–1089.
118.
DiederichK, SevimliS, DorrH, KostersE, HoppenM, LewejohannL, KlockeR, MinnerupJ, KnechtS, NikolS, SachserN, SchneiderA, GorjiA, SommerC, SchabitzWR (2009)The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: A characterization of G-CSF-deficient mice. J Neurosci29, 11572–11581.
119.
StanleyER, BergKL, EinsteinDB, LeePS, PixleyFJ, WangY, YeungYG (1997) Biology and action of colony–stimulating factor-1. Mol Reprod Dev46, 4–10.
120.
BoissonneaultV, FilaliM, LessardM, ReltonJ, WongG, RivestS (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain132, 1078–1092.
121.
MildnerA, SchmidtH, NitscheM, MerklerD, HanischUK, MackM, HeikenwalderM, BruckW, PrillerJ, PrinzM (2007) Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci10, 1544–1553.
122.
AjamiB, BennettJL, KriegerC, TetzlaffW, RossiFM (2007) Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci10, 1538–1543.
123.
ChenD, XieR, ShuB, LandayAL, WeiC, ReiserJ, SpagnoliA, TorquatiA, ForsythCB, KeshavarzianA, SumnerDR (2018) Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging. Ann N Y Acad Sci. doi: 10.1111/nyas.13945
124.
Tapia-RojasC, InestrosaNC (2018) Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease. Neural Regen Res13, 1705–1710.
125.
Dengler-CrishCM, BallHC, LinL, NovakKM, CooperLN (2018) Evidence of Wnt/beta-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer’s disease. Neurobiol Aging67, 148–158.
126.
LaFerlaFM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci3, 862–872.
127.
GreenKN, LaFerlaFM (2008) Linking calcium to Abeta and Alzheimer’s disease. Neuron59, 190–194.
GibsonGE, ThakkarA (2017) Interactions of mitochondria/metabolism and calcium regulation in Alzheimer’s Disease: A Calcinist point of view. Neurochem Res42, 1636–1648.
